CGChristopher van der Gast

Christopher van der Gast

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Christopher van der Gast has a total of 170 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Distinct gastrointestinal symptom phenotypes in adults with cystic fibrosis are linked to complications and medication use: the GRAMPUS-CF study

    by J. Holaman, D. Sills, H. Saumtally, C. Johnson, A. Recto, R. Marsh, A. Prayle, K. Gathercole, T. Monaghan, L. Marciani, et al.

  • Open Access

    Remodelling of cystic fibrosis respiratory microbiota in response to extended elexacaftor–tezacaftor–ivacaftor therapy

    by Helen Gavillet, Lauren R. Hatfield, Michelle Hardman, Ryan Marsh, Gisli G. Einarsson, Christina S. Thornton, Michael D. Parkins, Jamie Duckers, Jennifer M. Bomberger, Yasmin Hilliam, et al.

    Background: Cystic fibrosis (CF) has profoundly changed since the introduction of CF Transmembrane Conductance Regulator modulator therapies (CFTRmt), a class of medications that improve function of the CFTR protein encoded by certain CF-causing gene mutations. Amongst these, the triple combination therapy elexacaftor–tezacaftor–ivacaftor (ETI) has been the most impactful and widely used to date. Given chronic respiratory infection and concomitant inflammation is the leading cause of morbidity and early mortality for the majority in CF, what is not certain are the long-term effects of ETI therapy on the respiratory microbiota and pathogens embedded within. Here, we assessed the effects of ETI CFTRmt over 3 years on the respiratory microbiota, using sputum and cough swab samples, from a multi-centre cohort of 276 adults with CF (awCF) from 6 CF centres in the UK, USA, and Canada, and compared to a non-CF healthy cohort. Results: Using Kruskal–Wallis analyses with post hoc Dunn’s tests, Wilcoxon signed-rank tests, and PERMANOVA analyses with Bonferroni correction, we determined that respiratory microbiota characteristics (diversity, dominance, and composition) became decreasingly like those of awCF pre-ETI and remodelled to align more with the healthy cohort, where canonical CF pathogens increasingly became less ecologically important in terms of their distributions and abundances across awCF with increased duration on therapy. However, the on-ETI microbiota was impeded from becoming fully ‘healthy’ due to continued antibiotic exposure and irreversible lung damage experienced by awCF. Specifically, we found that azithromycin, an antibiotic widely used principally for its immunomodulatory benefits, was associated with adverse effects on the respiratory microbiota nullifying the observed positive effects of ETI treatment. Our results indicated that when administered alongside ETI therapy, azithromycin contributed to a pre-ETI microbiota dysbiosis and enabled enhanced persistence of emblematic CF pathogens. Conclusions: The highly anticipated introduction of ETI CFTRmt has greatly changed the course of CF for many people living with this inherited disease. Here, we find that ETI CFTRmt enabled positive remodelling of the respiratory microbiota towards a healthy-like state. However, azithromycin appeared to impede total remodelling, making it an ideal candidate for evaluation for discontinuation in the CFTRmt era. While traditional pathogens become less ecologically important, the potential evolution and emergence of virulent strains should be investigated. Additionally, the impacts and implications of ETI therapy on the understudied fungal microbiota should also be explored.

  • Towards a gut-lung axis role in pwCF on CFTR modulators: rationale, clinical evidence and perspectives

    by Maxime Lefranc, Eloise Ramel, Ryan Marsh, James M Tricker, Christopher van der Gast, Jennifer M. Bomberger, Laurence Delhaes

  • Open Access

    The gut microbiome: Recent findings and future opportunities in cystic fibrosis

    by Ryan Marsh, James M Tricker, Laurence Delhaes, Jennifer M Bomberger, Christopher van der Gast


  • Open Access

    Rapid assembly and functional differentiation of the soil surface microbiome in temperate agricultural soil

    by Christopher James O'GRady, Sally Hilton, Emma Picot, Sebastien Raguideau, Christopher Quince, Christopher J. van der Gast, Hendrik Schäfer, Gary D. Bending

  • Open Access

    Distinct Gastrointestinal Symptom Phenotypes in Adults with Cystic Fibrosis are linked to complications and medication use

    by Jemila R Holaman, Darren J Sills, Hisham A Saumtally, Charlotte C Johnson, Arantxa A Recto, Ryan Marsh, Andrew Prayle, Tanya M Monaghan, Luca Marciani, Robin C Spiller, et al.

    Background and aims: Gastrointestinal symptoms remain common in adults with cystic fibrosis (CF) despite cystic fibrosis transmembrane conductance regulator modulator use, suggesting persistent and heterogeneous gut dysfunction. This prospective observational study tests the hypothesis that distinct gut symptom phenotypes in CF can be observed and linked to underlying mechanisms. Methods: Adults from three UK CF centres completed the Gastrointestinal Symptom Rating Scale, Patient Assessment of Constipation Symptoms and a bowel-habit questionnaire. Latent class analysis using an ordinal logistic model was applied to 36 symptom indicators. Associations between phenotypes and demographic, clinical, and treatment variables were examined using generalised linear models. Results: Three hundred participants completed questionnaires (54% male; median 31 years). We identified four symptom phenotypes: mild; moderate-constipation predominant; moderate-diarrhoea predominant and severe. The severe phenotype was associated with gastroesophageal reflux (RRR 2.86; 95%CI: 1.30-6.31; p=0.009), distal intestinal obstruction syndrome (RRR 2.46; 95%CI: 1.04-5.81; p=0.04), proton pump inhibitor (RRR 3.29; 95%CI 1.39-7.74; p=0.007), and laxative use (RRR 6.13; 95%CI 2.54-14.84; p<0.001). CF-related liver disease was associated with both moderate-constipation and diarrhoea phenotypes, respectively (RRR 2.08; 95%CI 1.13-3.81; p=0.018; RRR 2.11; 95%CI 1.03-4.29; p=0.04). There was a lower likelihood of long-term oral antibiotic use in the moderate-constipation phenotype (RRR 0.53; 95%CI 0.3-0.92; p=0.025) and moderate-diarrhoea phenotype (RRR 0.46; 95%CI 0.24-0.91; p=0.025). Conclusions: Four distinct symptom phenotypes were identified, independent of demographics and pancreatic status, but associated with specific complications and medication profiles. These phenotypes provide a framework for mechanistic studies within the GRAMPUS-CF cohort and precision management of CF-related gut disease.


  • Open Access

    Remodelling of cystic fibrosis respiratory microbiota in response to extended Elexacaftor–Tezacaftor–Ivacaftor therapy

    by Helen Gavillet, Lauren R Hatfield, Michelle Hardman, Ryan Marsh, Gisli G Einarsson, Christina S Thornton, Michael D Parkins, Jamie Duckers, Jennifer M Bomberger, Yasmin Hilliam, et al.

    Background: Cystic fibrosis (CF) has profoundly changed since the introduction of CF Transmembrane Conductance Regulator modulator therapies (CFTRmt), a class of medications that improve function of the CFTR protein encoded by certain CF-causing gene mutations. Amongst these, the triple combination therapy elexacaftor-tezacaftor-ivacaftor (ETI) has been the most impactful and widely used to date. Given chronic respiratory infection and concomitant inflammation is the leading cause of morbidity and early mortality for the majority in CF, what is not certain are the long-term effects of ETI therapy on the respiratory microbiota and pathogens imbedded within. Here we assessed the long-term effects of ETI CFTRmt over 3-years on the respiratory microbiota of a multi-centre cohort of 276 adults with CF (awCF) from 6 CF centres in the UK, USA, and Canada, and compared to a non-CF healthy cohort. Results: We determined that respiratory microbiota characteristics (diversity, dominance, and composition) became decreasingly like those of awCF pre-ETI and remodelled to align more with the healthy cohort, where canonical CF pathogens increasingly became less ecologically important in terms of their distributions and abundances across awCF with increased duration on therapy. However, the on-ETI microbiota was impeded from becoming fully ‘healthy’ due to continued antibiotic exposure and irreversible lung damage experienced by awCF. Specifically, we found that azithromycin, an antibiotic widely used principally for its immunomodulatory benefits, had adverse effects on the respiratory microbiota nullifying the observed positive effects of ETI treatment. When administered alongside ETI-therapy, the use of azithromycin maintained a pre-ETI microbiota dysbiosis and enabled enhanced persistence of emblematic CF pathogens. Conclusions: The highly anticipated introduction of ETI CFTRmt has greatly changed the course of CF for many people living with this inherited disease. Here we find that ETI CFTRmt enabled positive remodelling of the respiratory microbiota towards a healthy-like state. However, azithromycin impeded total remodelling, making it an ideal candidate for evaluation for discontinuation in the CFTRmt era. While traditional pathogens become less ecologically important the potential evolution and emergence of virulent strains should be investigated. Additionally, the impacts and implications of ETI therapy on the understudied fungal microbiota should also be explored.

  • Open Access

    Nontuberculous mycobacteria remodel lung microbiota in cystic fibrosis-associated respiratory infections

    by Michelle Hardman, Sarah Higgi, Liam Hanson, Kristin Schutz, Matthew J. Wargo, Charlotte C. Teneback, Thomas W. V. Daniels, Christopher van der Gast, Damian W. Rivett

    Nontuberculous mycobacterial (NTM) infections in people with cystic fibrosis (pwCF) can have detrimental effects on prognosis and pose significant challenges to treatment. However, there are still questions regarding the contribution and influence of NTMs on the respiratory microbiome and the mechanisms by which NTMs cause infections. Here, we investigate the impact of NTM infection on microbiome composition and lung function (percent predicted forced expiratory volume in 1 second). Primary comparisons were between culture-positive cohorts for Mycobacterium avium complex and Mycobacterium abscessus complex and those who were culture-negative for NTMs and attending outpatient clinics. Additionally, the consequence of cystic fibrosis transmembrane conductance regulator (CFTR) modulator therapy status and positive NTM culture was assessed in terms of microbiome change. Our data suggest that the presence of NTM significantly alters the diversity and the composition of the lung microbiota in pwCF, including those receiving CFTR modulator therapies. Importantly, significant associations were detected between NTM presence and changes in abundance of Pseudomonas aeruginosa and Burkholderia cepacia complex members, inferring modulatory effects of NTMs on respiratory microbiomes. This study contributes to the understanding of NTM infection and these organisms’ interaction with the respiratory microbiome and CFTR modulator therapy, highlighting the need for further research in this area. IMPORTANCE: The influence of NTM infection in pwCF is still debated, and the extent of their contribution to mortality and morbidity is still questioned. Findings in this study highlight a link between the presence of NTMs and significant alterations in the composition of the respiratory microbiome, particularly with respect to some of the canonical CF pathogens, especially Pseudomonas aeruginosa and members of the Burkholderia cepacia complex. This indicates that complex relationships are occurring within the microbiome. This study further contributes to the understanding of NTM infection in pwCF, with and without CFTR modulator therapy, and highlights the need for further research in this area. The knowledge gained from this study has implications for treatment strategies and management, ultimately aiming to improve and prolong the lives of pwCF.


  • Open Access

    Species turnover within cystic fibrosis lung microbiota is indicative of acute pulmonary exacerbation onset

    by Leah Cuthbertson, Lauren Hatfield, Helen Gavillet, Michelle Hardman, Ryan Marsh, Damian W. Rivett, Christopher van der Gast

    Background: Acute pulmonary exacerbations (PEx) are associated with increased morbidity and earlier mortality for people living with cystic fibrosis (pwCF). The most common causes of PEx in CF are by bacterial infection and concomitant inflammation leading to progressive airway damage. To draw attention to the seriousness of PEx they have been labelled as ‘lung attacks’, much like a ‘heart attack’ for acute myocardial infarction. Treatment typically starts when a pwCF presents with worsening respiratory symptoms. Hence, there is a pressing need to identify indicative biomarkers of PEx onset to allow more timely intervention. Set within an ecological framework, we investigated temporal microbiota dynamics to connect changes in the lung microbiota of pwCF to changes in disease states across a PEx event. Results: Species-time relationships (STR) describe how the richness of a community changes with time, here STRs were used to assess temporal turnover (w) within the lung microbiota of each pwCF (n = 12, mean sample duration 315.9 ± 42.7 days). STRs were characterised by high interpatient variability, indicating that turnover and hence temporal organization are a personalized feature of the CF lung microbiota. Greater turnover was found to be significantly associated with greater change in lung function with time. When microbiota turnover was examined at a finer scale across each pwCF time series, w-values could clearly be observed to increase in the exacerbation period, then peaking within the treatment period, demonstrating that increases in turnover were not solely a result of perturbations caused by PEx antibiotic interventions. STR w-values have been found to have a remarkable degree of similarity for different organisms, in a variety of habitats and ecosystems, and time lengths (typically not exceeding w = 0.5). Here, we found w-values soon increased beyond that. It was therefore possible to use the departure from that expected norm up to start of treatment to approximate onset of PEx in days (21.2 ± 8.9 days across the study participants). Conclusions: Here, we illustrate that changes in turnover of the lung microbiota of pwCF can be indicative of PEx onset in considerable advance of when treatment would normally be initiated. This offers translational potential to enable early detection of PEx and consequent timely intervention.


  • Open Access

    Rapid Assembly and Functional Differentiation of the Soil Surface Microbiome in Temperate Agricultural soil

    by Christopher James O’GRady, Sally Hilton, Emma Picot, Sebastien Raguideau, Christopher Quince, Christopher J. van der Gast, Hendrik Schäfer, Gary Douglas Bending

    The surface of dryland soils is typically covered by biological soil crusts (BSC) dominated by cyanobacteria, lichens or moss which contribute key ecosystem functions. However, while photosynthetic biota have been observed on the surface of temperate agricultural soils, understanding of the development, biodiversity and functional significance of these communities is extremely limited. We investigated the temporal development of the soil surface community following tillage and during subsequent growth of a wheat crop. Amplicon analysis showed that establishment of the soil surface microbiome was rapid over the winter period, with distinct communities of phototrophs, bacteria and protists detected 60 days after tillage. There was rapid succession with yellow-green algae (Xanthophyceae) dominating early stages of development, followed by Cyanobacteria and Charophytes and finally moss. Temporal dynamics of fungal and protist communities was influenced by eDNA deposition from plant pathogens inhabiting the crop canopy and wild animal parasites. For all groups, assembly processes in the surface soil became increasingly dominated by dispersal limitation over time while assembly of bulk soil communities became predominantly influenced by drift. Metagenome analysis showed that the soil surface had developed a distinct functional profile relative to bulk soil after 9 months, enriched in photosynthetic processes which were largely from eukaryotic algae rather than cyanobacteria. Additionally the 3-Hydroxypropionate bicycle and reductive TCA carbon fixation pathways were enriched in surface soil. The abundance of genes involved in heterotrophic carbon, nitrogen, phosphorus and sulphur cycling processes were also enriched in surface soil. This included reads of carbohydrate active enzymes, nitrification, denitrification and sulphate reduction genes, largely attributed to the enrichment of Actinobacteria, Bacteroidetes and Proteobacteria in the soil surface. Overall, we show overlap in dominant phototrophic taxa between temperate agricultural and BSC in arid soils, but with notable differences, including abundance of Xanthphycae and Charophytes. Furthermore, the functional signatures of the soil surface communities indicate that they may play an important role in the delivery of ecosystem functions in temperate agricultural systems.